Jam

Preliminary phase 2 results from the REJOICE-Ovarian01 trial show raludotatug deruxtecan (R-DXd) demonstrates clinically significant response in recurrent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. The study observed a 50.5% objective response rate across all doses. The Phase 3 portion will evaluate a 5.6 mg/kg dose of R-DXd against chemotherapy. R-DXd, a CDH6-directed antibody drug conjugate, is being jointly developed by Daiichi Sankyo and Merck, highlighting collaborative efforts in oncology drug development due to high unmet needs in late stage ovarian cancer.

AstraZeneca and Daiichi Sankyo’s DATROWAY met dual primary endpoints in the TROPION-Breast02 Phase III trial for locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) patients. DATROWAY demonstrated a statistically significant and clinically meaningful improvement in both overall survival (OS) and progression-free survival (PFS) versus chemotherapy. The trial showed a 43% reduction in disease progression or death risk and a 5-month improvement in median OS versus chemotherapy. Detailed results will be presented at the 2025 ESMO Congress.

Corcept Therapeutics presented Phase 3 ROSELLA trial data at ESMO 2025, showing relacorilant plus nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer patients, including those progressing on PARP inhibitors. The combination also demonstrated a favorable safety profile. Corcept is expanding the Phase 2 BELLA trial to include platinum-sensitive ovarian and endometrial cancer arms, with initial results expected in late 2026. The FDA has granted relacorilant priority review for platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.

The TROPION-Breast02 phase 3 trial, presented at ESMO 2025, shows DATROWAY significantly improved overall survival (OS) and progression-free survival (PFS) versus chemotherapy in locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) patients ineligible for immunotherapy. DATROWAY reduced the risk of disease progression or death by 43% and improved median OS by 5 months. The objective response rate was 62.5% with DATROWAY versus 29.3% with chemotherapy, and median duration of response was 12.3 versus 7.1 months, respectively.

Delcath Systems, Inc. announced preliminary Q3 2025 results, with total CHEMOSAT and HEPZATO KIT revenue reaching $20.5 million and net income at $0.8 million. The company projects full-year revenue between $83 and $85 million, representing a 150% treatment volume increase. Positive adjusted EBITDA and operating cash flow are anticipated for each quarter of 2025. A conference call is scheduled for October 20 to discuss results and the CHOPIN trial. The company focuses on liver cancer therapies, including HEPZATO KIT and CHEMOSAT.

Sify Technologies (NASDAQ: SIFY) will release its Q2 FY2025-2026 financial results on October 25, 2025, before market open. A conference call to discuss results will be held on October 27, 2025, at 8:30 AM ET, hosted by Raju Vegesna and M P Vijay Kumar. Sify, a leading Indian ICT solutions provider, focuses on data centers, cloud, networks, and security, catering to India’s digital economy. Webcast and replay details are available on Sify’s website.

The KEYNOTE-B96 Phase 3 trial demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with KEYTRUDA plus chemotherapy with or without bevacizumab in platinum-resistant recurrent ovarian cancer. The study showed PFS benefits in the overall population and OS benefits in patients with PD-L1 expressing tumors. The FDA has granted priority review to Merck’s sBLA for this combination, with a PDUFA date of Feb. 20, 2026, potentially changing treatment for this challenging disease.

On October 18, 2025, Nasdaq halted trading of Etoiles Capital Group Co., Ltd. (EFTY) pending further information from the company. This follows an earlier SEC suspension of EFTY trading from October 6-17, 2025. The last reported sale price was $15.02. Trading will remain halted until Etoiles Capital Group satisfies Nasdaq’s information request. The SEC previously suspended trading due to concerns about the accuracy of company information. Analysts are monitoring the situation, advising caution to investors.

NuCana (NCNA) presented data at ESMO 2025 demonstrating synergistic effects of NUC-7738 with PD-1 inhibitors in patient-derived organoids from renal cell carcinoma patients, enhancing tumor cell killing. These findings align with the Phase 1/2 NuTide:701 study, showing a favorable safety profile and tumor reduction in PD-1 refractory melanoma. Regulators approved a study expansion to enroll 28 more patients. NuCana plans to meet with the FDA to discuss a potential registration strategy for NUC-7738.

Merck and Eisai announced five-year follow-up data from the Phase 3 KEYNOTE-775/Study 309 trial, demonstrating a sustained survival benefit of KEYTRUDA plus LENVIMA compared to chemotherapy in patients with advanced endometrial carcinoma. For pMMR patients, the five-year OS rate was 16.7% for the combination versus 7.3% for chemotherapy. These long-term results offer a promising treatment option for this aggressive cancer, despite the associated adverse events. The combination is approved in the U.S., EU, and Japan for specific patients.